Report Overview

The EU Polycystic Ovarian Syndrome Treatment market was valued at XX Million US$ in 2019 and is projected to reach XX Million US$ by 2028, at a CAGR (Compound Annual Growth Rate) of XX% during the forecast period

PCOS is the most frequent endocrine disorder in women linked to metabolic dysfunction and the most frequent cause of female infertility. PCOS has a high unmet medical need due to limited treatment options. PCOS is characterised by high levels of androgens (male hormones such as testosterone) produced in the ovaries, adrenals and fat tissue leading to the typical skin signs of androgen access such as hair loss and acne. Ovarian cysts give the syndrome its name and are associated with irregular menstrual cycle and the above described infertility. Most of the PCOS patients suffer from obesity and more than half are afflicted with insulin resistance, both driven by this endocrinological disorder



Market Growth Drivers

The prevalence of the PCOS are growing which is fuelling growth of the PCOS treatment market. Additionally, growing awareness among the patient population about the availability of the treatment are fuelling growth of the PCOS treatment market. Also, The players in the market are currently focusing on the unmet need of the market and on strengthening their pipelines to leverage the opportunities; the commercialization of these robust pipelines is expected to propel market growth